Adenosine Diphosphate Ribose - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Adenosine Diphosphate Ribose

The Experts below are selected from a list of 198 Experts worldwide ranked by ideXlab platform

Kyaw Zin Thein – 1st expert on this subject based on the ideXlab platform

  • A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of hematological toxicities in patients with cancer treated with poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors.
    Journal of Clinical Oncology, 2018
    Co-Authors: Anita Sultan, Sriman Swarup, Yin Mon Myat, Htay Htay Aung, Kalpana Panigrahi, Kyaw Zin Thein

    Abstract:

    217Background: Poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors have shown to benefit in DNA repair-deficient tumors by enhancing synthetic lethality in cancer cells and are currently…

  • Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with poly Adenosine Diphosphate Ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
    Journal of Clinical Oncology, 2018
    Co-Authors: Anita Sultan, Sriman Swarup, Yin Mon Myat, Khaing Khaing Htwe, Aung Myo Hein, Tsujung Yang, Kyaw Zin Thein

    Abstract:

    219Background: Inhibition of poly Adenosine Diphosphate Ribose polymerase (PARP) enzymes terminates an alternative DNA repair pathway, resulting in synthetic lethality in homologous recombination deficient tumors. Many PARP inhibitors have shown to improve survival in many solid tumors with noteworthy safety concerns. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of gastrointestinal (GI) and hepatic toxicities. Methods: We conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018. Phase III RCTs that mention GI toxicities and elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: 3188 patients from 7 phase III RCTs with breast, ov…

  • Discontinuation of poly(Adenosine DiphosphateRibose) polymerase inhibitors due to adverse events in patients with recurrent ovarian cancer: A meta-analysis of three phase III trials.
    Journal of Clinical Oncology, 2018
    Co-Authors: Kyaw Zin Thein, Anita Sultan, Sriman Swarup, Yin Mon Myat, Catherine Jones, Fred Hardwicke, Sanjay Awasthi

    Abstract:

    118Background: Ovarian cancer is the fifth leading cause of cancer-related death among women. Poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors maintenance has shown to improve survival in patients with recurrent ovarian cancer. Yet, there are notable adverse events which led to treatment discontinuation, interruption, or dose reduction. We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of PARP inhibitors discontinuation due to adverse events. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018 were queried. Phase III RCTs which employed PARP inhibitors maintenance in ovarian cancer and mentioned treatment interruption, dose reduction and treatment discontinuation due to adverse events were included. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: Three phase III RCTs with a total…

Anita Sultan – 2nd expert on this subject based on the ideXlab platform

  • A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of hematological toxicities in patients with cancer treated with poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors.
    Journal of Clinical Oncology, 2018
    Co-Authors: Anita Sultan, Sriman Swarup, Yin Mon Myat, Htay Htay Aung, Kalpana Panigrahi, Kyaw Zin Thein

    Abstract:

    217Background: Poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors have shown to benefit in DNA repair-deficient tumors by enhancing synthetic lethality in cancer cells and are currently…

  • Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with poly Adenosine Diphosphate Ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
    Journal of Clinical Oncology, 2018
    Co-Authors: Anita Sultan, Sriman Swarup, Yin Mon Myat, Khaing Khaing Htwe, Aung Myo Hein, Tsujung Yang, Kyaw Zin Thein

    Abstract:

    219Background: Inhibition of poly Adenosine Diphosphate Ribose polymerase (PARP) enzymes terminates an alternative DNA repair pathway, resulting in synthetic lethality in homologous recombination deficient tumors. Many PARP inhibitors have shown to improve survival in many solid tumors with noteworthy safety concerns. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of gastrointestinal (GI) and hepatic toxicities. Methods: We conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018. Phase III RCTs that mention GI toxicities and elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: 3188 patients from 7 phase III RCTs with breast, ov…

  • Discontinuation of poly(Adenosine DiphosphateRibose) polymerase inhibitors due to adverse events in patients with recurrent ovarian cancer: A meta-analysis of three phase III trials.
    Journal of Clinical Oncology, 2018
    Co-Authors: Kyaw Zin Thein, Anita Sultan, Sriman Swarup, Yin Mon Myat, Catherine Jones, Fred Hardwicke, Sanjay Awasthi

    Abstract:

    118Background: Ovarian cancer is the fifth leading cause of cancer-related death among women. Poly Adenosine Diphosphate Ribose polymerase (PARP) inhibitors maintenance has shown to improve survival in patients with recurrent ovarian cancer. Yet, there are notable adverse events which led to treatment discontinuation, interruption, or dose reduction. We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of PARP inhibitors discontinuation due to adverse events. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018 were queried. Phase III RCTs which employed PARP inhibitors maintenance in ovarian cancer and mentioned treatment interruption, dose reduction and treatment discontinuation due to adverse events were included. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: Three phase III RCTs with a total…

Jun Zheng – 3rd expert on this subject based on the ideXlab platform

  • overactivation of poly Adenosine phosphate Ribose polymerase 1 and molecular events in neuronal injury after deep hypothermic circulatory arrest study in a rabbit model
    The Journal of Thoracic and Cardiovascular Surgery, 2007
    Co-Authors: Yue Tang, Cun Long, Liangxin Tian, Zhengyi Feng, Jun Zheng

    Abstract:

    Objective Although deep hypothermic circulatory arrest has been known to induce neuronal injury, the molecular mechanism of this damage has not been identified. We studied the key molecular mediators through cellular energy failure, excitotoxicity, and overactivation of poly(Adenosine DiphosphateRibose) polymerase 1 in brain tissues of a rabbit model of deep hypothermic circulatory arrest similar to clinical settings. Methods We established 2 models of cardiopulmonary bypass (n = 15) and deep hypothermic circulatory arrest (n = 15) associated with cerebral microdialysis in rabbits. Deep hypothermic circulatory arrest lasted for 60 minutes. The measurements of glucose, lactate, pyruvate, and glutamate collected by means of microdialysis were quantified by using a microdialysis analyzer and high-performance liquid chromatography. The overactivation of poly(Adenosine DiphosphateRibose) polymerase 1 was assessed by detecting immunostaining of poly(Adenosine DiphosphateRibose). Histologic studies were used to identify neuronal morphologic changes and terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end-labeling staining and poly(Adenosine DiphosphateRibose) polymerase 1 Western blotting were used to identify apoptotic cells and early apoptotic signals. Results Deep hypothermic circulatory arrest significantly increased the lactate/pyruvate and lactate/glucose ratios and the glutamate value, whereas cardiopulmonary bypass did not ( P P P Conclusions This study demonstrated that deep hypothermic circulatory arrest results in an overactivation of poly(Adenosine DiphosphateRibose) polymerase 1, and that there were molecular events consisting of cellular energy failure, excitotoxicity, overactivation of poly(Adenosine DiphosphateRibose) polymerase 1, and necrosis and/or apoptosis in neuronal injury.